LNTH — Lantheus Holdings, Inc.

Lantheus (LNTH) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $377.3 million, a 1.2% increase year-over-year; adjusted revenue growth of 8.6% when excluding $25.2 million from divested spec revenues.
• Segment Performance:
  • Oncology (PYLARIFY): $240.9 million, down 6.5% year-over-year.
  • Neurology (NEUROCEQ): $35.4 million, with 14.3% growth from Q4 2025.
  • Cardiology (DEFINITY): $84.6 million, up 6.8% year-over-year.
  • Strategic Partnerships: $16.3 million, up 52.1%.
• Gross Profit Margin: 67.0%, stable compared to Q1 2025.
• Operating Income: $129.1 million, a decrease of 10.5%.
• Net Income: $118.4 million; adjusted net income of $95.8 million, down 12.5%.
• Earnings Per Share (EPS): GAAP EPS of $1.80; adjusted EPS of $1.46, down 4.6%.
• Cash Flow: Operating cash flow of $125.1 million; free cash flow of $121.9 million.

2. Strategic Updates and Business Highlights

• Product Launches: FDA approval of PYLARIFY TRUVU, a new PSMA PET imaging agent, expected to enhance patient access and manufacturing efficiency starting Q4 2026.
• Market Leadership: Continued focus on maintaining leadership in PSMA PET and expanding NEUROCEQ's market share.
• Pipeline Advancements: Tentative FDA approval for PNT2003 and progress on MK-6240 for Alzheimer's imaging.
• Operational Focus: Emphasis on disciplined capital allocation and strategic investments in radio diagnostics.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reiterated at $1.4 billion to $1.45 billion; adjusted EPS forecasted between $5.00 and $5.25.
• Market Growth Expectations: Anticipated low teens growth in the PSMA PET market for 2026, with a focus on sustaining PYLARIFY volume growth and executing the transition to TRUVU.

4. Bad News, Challenges, or Points of Concern

• Oncology Revenue Decline: PYLARIFY revenue decreased by 6.5%, raising concerns about competitive pressures and pricing dynamics.
• Regulatory Delays: PDUFA date for Actinium extended by three months, potentially impacting launch timelines.
• Market Competition: Ongoing competitive dynamics in the PSMA PET imaging market, with potential new entrants being monitored.
• Operational Costs: Increased operating expenses due to acquisitions and investments in R&D, which may pressure margins.

5. Notable Q&A Insights

• Guidance Prudence: Management indicated that the decision to maintain guidance was partly due to the upcoming CEO transition and the need for caution amid competitive pressures.
• NEUROCEQ Market Position: NEUROCEQ is the second most utilized beta amyloid PET imaging agent, with growth driven by increased utilization and expanding market opportunities.
• TRUVU Transition Strategy: Emphasis on ensuring customer readiness and operational support for the transition to PYLARIFY TRUVU, with a focus on seamless integration and reimbursement processes.
• Market Monitoring: Management is vigilant about potential new entrants in the PSMA imaging market but remains confident in their established franchise and customer relationships.

Overall, Lantheus reported a solid start to 2026 with strategic advancements and a focus on maintaining market leadership, despite facing challenges in revenue growth and competitive pressures.